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Abstract
Background: Elevated levels of fetuin-A are associated with increased risks of metabolic syndrome, type 2 diabetes
and nonalcoholic fatty liver disease. This meta-analysis investigated whether exercise interventions can reduce
fetuin-A in adults.
Methods: We searched clinical trials that objectively assessed fetuin-A and included study arms with exercise
intervention. The pre-intervention and post-intervention data were used for meta-analysis. The effect sizes were
calculated as standardized mean differences or changes in fetuin-A and expressed as Hedges’ g using random-
effects models.
Results: The overall Hedges’ g for fetuin-A in all included interventions was − 0.640 (95%CI − 1.129 to − 0.151; n =
9), but this effect was not observed in obese (g = − 0.096; 95%CI, − 0.328 to 0.135) and type 2 diabetes/dysglycemia
(g = − 0.56; 95%CI, − 1.348 to 0.236) individuals. Additionally, the random-effects meta-regression analysis showed
that there was not a greater decrease in fetuin-A in individuals who achieved greater body mass index reductions
(regression coefficient = 0.065; 95%CI, − 0.185 to 0.315).
Conclusion: Supervised exercise is associated with reductions in fetuin-A levels in adults and elderly. However, the
results of the present meta-analysis should be interpreted with caution because of the variety of type of exercises
and individual obesity related-disorders involve. Therefore, additional high-quality randomized controlled trials
describing the effect of supervised exercise interventions on fetuin-A in adults are still needed.
Keywords: Fetuin-a, Obesity, Type 2 diabetes, Metabolic syndrome, Cardiovascular disease, Exercise training, Meta-
analysis, Systematic review
Background
Human fetuin-A (formerly named α2-Heremans-Schmid
glycoprotein) is a 64-kDa glycoprotein that is found in
relatively high concentrations in serum (300–1000 μg/ml)
[1]. Fetuin-A is mainly expressed and secreted from the
liver and adipose tissue [2]. Recent studies suggest that
the liver may control whole-body energy homeostasis
through the regulation of glucose and lipid metabolism by
the secretion of fetuin-A [3, 4]. For example, in an animal
model of diet-induced obesity that is commonly associated
with hepatic steatosis, an increase in fetuin-A mRNA
expression was observed in the liver [4]. Cross-sectional
[5, 6] and large cohort studies [7, 8] have demonstrated
consistently that elevated fetuin-A levels are associated
with increased risks of subclinical and clinical cardiovas-
cular disease (CVD).
Circulating levels of fetuin-A are increased in obesity
and related disorders such as the metabolic syndrome,
type 2 diabetes, and myocardial infarction/stroke [9–12].
Fetuin A stimulates the production of pro-inflammatory
cytokines from adipocytes and macrophages [13] and
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acts as an endogenous ligand for Toll-like receptor 4,
which enables free fatty acids to activate Toll-like recep-
tor 4 signaling to induce insulin resistance [14]. More-
over, fetuin-A levels is also associated with type 2
diabetes risk [9] due to been shown to inhibit skeletal
muscle insulin receptor tyrosine phosphorylation and re-
duce Akt activity, which in turn, contributes to de-
creased peripheral glucose uptake [15]. Interestingly, this
liver-derived protein is also associated with fatty liver
and correlates with non-alcoholic fatty liver disease
(NAFLD) in humans [16].
Recent research studies have investigated the mecha-
nisms that underlie the relationship between fetuin-A and
subclinical-clinical CVD-related complications [17, 18].
Trepanowski et al. reported fetuin-A is involved in the
mechanism regulating the insulin downstream signaling
pathway and acts as an inhibitor of insulin resistance in
muscle, liver and fat [11]. Fetuin-knockout mice exhibit
improved glucose and insulin tolerance and are resistant
to high-fat diet-induced weight gain [19]. Although the
regulation of fetuin-A synthesis is not completely under-
stood, its strong association within metabolic diseases has
made it an attractive target for the development of novel
research approaches related to metabolic health, such as
insulin sensitivity, glucose tolerance or circulating lipid
level treatments.
In particular, fetuin-A is the contributor which plays a
critical role in the impairment of two metabolic sensors,
Sirtuin 1 and AMP-activated protein kinase, in inflamed
adipocytes of high fat diet mice [20]. Several studies was
proposed that increased circulating fetuin-A in humans
after a chronic exercise program may promote increased
weight loss and improved metabolic control through ele-
vation of adiponectin expression [20] and decrease of
inflammatory cytokines in the liver and muscle [21] via
fetuin-A inhibition through the AMP-activated protein
kinase-nuclear factor kappa-light-chain-enhancer of acti-
vated B cells pathway [4]. Furthermore, fetuin-A directly
correlated with two cardiometabolic risk markers, Apo B
and C-reactive protein that, together with insulin resist-
ance, are important components of the metabolic syn-
drome. This hypothesis seemed plausible, as studies
demonstrated fetuin-A lowered expression of stimulated
oxygen consumption and had an inverse association with
blood postprandial insulin, c-peptide, and lipid peroxida-
tion levels [21] and a positive association with adiponec-
tin concentrations [22].
The exact role of exercise in regulating circulating
fetuin-A concentration remains to be fully established. As
a possible biological link between physical exercise and
fetuin-A levels, cardiorespiratory fitness and muscular
strength are inversely associated with liver fat and abdom-
inal obesity [23, 24], and fetuin-A is associated with liver
fat accumulation in humans [25]. A few studies have
assessed the effects of lifestyle interventions such as hypo-
caloric diets [26] physical exercise [27, 28] or combined
interventions [29] on fetuin-A, showing contradictory
results. Some biological alterations promoting the protect-
ive effects of exercise on insulin sensitivity may be ex
plained by changes in circulating fetuin-A and free fatty
acids, supporting less toll-like receptor 4 signaling in adi-
pose tissue perhaps by modulating adipose tissue macro-
phages [30]. In general, results on the effects of exercise
on circulating fetuin-A have been rather ambiguous; di-
verse exercise amount and intensity within interventions
may explain the highly discrepant results thus far.
In 2015, Trepanowski et al. [31] published the first com-
prehensive review to exclusively focus on the relationship
between fetuin-A and obesity. To the best of the investiga-
tive team’s knowledge, no systematic review, with or with-
out meta-analysis, has analyzed the effects of exercise on
fetuin-A levels in humans. Hence, the present work was
undertaken [31]. Due to heterogeneity between studies in
terms of results, we used a meta-analytic approach to
determine the effectiveness of supervised exercise inter-
ventions on fetuin-A in adults.
Methods
Protocol and registration
The study was undertaken in accordance with the Pre-
ferred Reporting Items for Systematic Reviews and Meta
-Analyses (PRISMA) statement [32]. The review was
registered with PROSPERO (CRD42017073872) at the
University of York, UK. However, no study protocol was
published before the initiation of the meta-analysis. All
analyses were based on aggregate data from previously
published studies, and thus, no ethical approval was
required.
Eligibility criteria
The a priori inclusion criteria for this study were as fol-
lows: (1) adults aged 18 years old; (2) interventions of
physical exercise without hypocaloric diet intervention;
and (3) assessment of serum fetuin-A.
Information sources
A search of the literature was performed using the elec-
tronic databases Cochrane Central Register of Con-
trolled Trials (CENTRAL), EMBASE, and MEDLINE
(all: from 1998 until 15 November 2017). The terms
used were as follows: [‘Fetuin-A and ‘alpha2hsglycopro-
tein’ OR], [‘Exercise’ and ‘training’ and ‘physical activity’
and ‘sport’ OR].
Search
Two researchers (AG-H and RR-V) independently car-
ried out the search. As an example, the search strategy
in MEDLINE database was as follows: “Fetuin-A and
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alpha2hsglycoprotein” AND “metabolic risk” OR “car-
diometabolic risk” OR “type 2 diabetes” “metabolic syn-
drome” OR “obesity”) AND (“exercise” OR “physical
activity” OR “exercise intervention” OR “training”) AND
(“intervention” OR “program” OR “trial” OR “treatment”
OR “pre-post study”). Additionally, the reference lists of
retrieved studies were examined to identify other arti-
cles. Studies reported in languages other than English
were not explored.
Study selection
Two authors (AG-H and RR-V) independently screened
the titles and abstracts of potentially eligible studies
identified by the search strategy. If necessary, a third
researcher (MI) was consulted. The bibliographic man-
agement software EndNote version X7.0 for Windows
was used for all searches. Any differences between the
two authors were discussed and, if necessary, the third
author was referred to for arbitration. Reasons for exclu-
sion of identified articles were recorded in all cases.
Data collection process and data items
Two researchers (AG-H and RR-V) independently
abstracted all data. For each study, data were extracted
regarding the first author’s last name, year of publica-
tion, characteristics of the subjects, exercise programs
(type, frequency, duration, intensity, etc.), assessment of
fetuin-A, sample size, and mean values with correspond-
ing standard deviations of fetuin-A and BMI (pre- and
post-test). The reviewers created a study-specific data-
base in Excel (Microsoft Corp., USA) for data collection.
Any differences between the two authors were discussed
and, if necessary, the third author was referred to for
arbitration.
Risk of bias of individual studies
The methodological quality of non-RCT studies and
studies without a control group was assessed using the
Quality Assessment Tool for Quantitative Studies of the
Effective Public Health Practice Project (EPHPP) [33].
This tool is used to evaluate a variety of intervention
study designs, such as non-RCT or pre-post studies [33].
EPHPP assesses study quality in six domains: selection
bias, study design, confounders, blinding, data collection
method, and withdrawals/dropouts. Each study was
assessed for quality by 2 reviewers (AG-H and RR-V),
and any discrepancy in the final grade was resolved
through group discussion or discussion among the pri-
mary authors.
Summary measures
All analyses were carried out using Comprehensive
Meta-analysis Software (second version, Biostat, Engle-
wood, NJ, USA) to calculate the standardized mean
difference and expressed as Hedges’ g to correct for
possible small-sample bias [34]. For studies that were
randomized and non-randomized controlled trials, the
Hedges’ g was calculated taking the change outcome dif-
ference between the exercise and control groups and
then dividing that difference by the pooled standard
deviation of the change outcome difference. For single
group studies, the Hedges’ g value of the fetuin-A was
calculated by the mean pre- to post-intervention in each
study (i.e., in all cases the pre-intervention and the
post-intervention data were used to meta-analyze), divid-
ing the result by the pooled standard deviation, and cor-
recting for small sample bias. We used the continuous
random-effect analysis with the DerSimonian-Laird me
thod to pool results. For studies where means and stand-
ard deviations were not reported and could not be
obtained from the authors, we transformed dichotomous
data into the standardized mean difference using the for-
mulas implemented in Comprehensive Meta-analysis
[35] or used other statistics, such as t-values or exact
p-values to calculate the standardized mean difference.
In the cumulative meta-analysis, outcome data for
fetuin-A from all available studies were included sequen-
tially according to the year in which they first became
available.
Synthesis of results
Heterogeneity between trial results was tested with
Cochran’s Q test [34] and the I2 statistic. I2 values of <
25%, 25–50, and > 50% are considered to represent
small, medium, and large amounts of inconsistency [36].
Each study was deleted from the model once to analyze
its influence on the overall results.
Risk of bias across studies
Small-study effects was assessed in two ways: 1) visual
inspection of the asymmetry of the funnel plot and
Egger’s test of the intercept to test the symmetry of the
funnel plot [37].
Additional analysis
Subgroup analyses were conducted to determine
whether fetuin-A differed according to population char-
acteristics by stratifying the meta-analyses by each of
these factors (i.e., healthy, type 2 diabetes/dysglycemia
and obese) using the random-effect model. Additionally,
random-effects meta-regression analyses were used to
evaluate whether the results differed with BMI changes
(as Hedges’ g) [38]. The effect of individual studies on
the pooled Hedges’ g was assessed with influence ana-
lysis, in which the analysis was repeated omitting one
study at a time, to establish the contribution of each
study to the effect size.
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Patient involvement
Due to the nature of the study, no participants were
involved in the systematic review and meta-analysis. Fur-
thermore, no patients were involved in the development
of the research question or outcome measures, nor were
they involved in the design, implementation, recruit-
ment, or conduct of the study. Finally, no patients were
asked to advise on the interpretation or writing up of
the results. There are no plans to disseminate the results
of the research to the study participants.
Results
Study selection
A total of 189 studies were identified through the database
search. The titles and abstracts of the returned articles
were examined for suitability, leading to the retrieval of 23
full texts. Of those 13, 4 were rejected—3 because of the
type of intervention criterion (interventions with hypoca-
loric diet), and one because of the population issues (ado-
lescents). Nine trials met the inclusion criteria and were
included in the meta-analysis [5, 21, 27–30, 39–41]. A
flow diagram summarizing the study selection process of
the systematic review and meta-analysis is shown in Fig. 1.
Exclusion criteria and the list of excluded articles are in
online Additional file 1.
The characteristics of the nine studies included in the
systematic review sorted by study design are available in
Table 1. All studies were single-group pre-post design
except two randomized controlled trials [40, 41] and one
a randomized trial without a control group [21]. A total
of 163 individuals were included in the meta-analysis.
Two studies included only women [29, 39], one included
only men [30], and five included mixed samples of men
and women [5, 21, 27, 28, 40, 41] who were relative
healthy [30], were obese [21, 27–29, 39], suffered from
nonalcoholic fatty liver disease [21, 28], or had type 2
diabetes/dysglycemia or were undergoing hemodialysis
[5, 30, 41].
Relative to exercise programs, all studies used aerobic
exercise except two that used a combined aerobic plus
resistance exercise protocol (concurrent exercise) [29,
30]. Overall, the programs mainly used treadmill walk-
ing/running, cycle ergometer cycling and whole-body
resistance training. The study durations ranged from
one to 16 weeks, and the training frequency ranged from
three to seven times weekly with 40–70min session dur-
ation. All exercise interventions were supervised.
Measurement of fetuin-a
All studies measured fetuin-A using enzyme-linked im-
munosorbent assays (ELISA) according to the manufac-
turer’s protocols.
Risk of bias within studies
Only three trials had random allocation between groups
[21, 40, 41]. All studies provided points and estimates of
variability. Blinding of the participants and therapists
was not possible because of the nature of the interven-
tions. The studies’ “bias” score ranged from two to four
with a mean total score of 2.62.
Synthesis of results
Overall, supervised exercise training was associated with
a significant reduction in the random-effects models (g
= − 0.640; 95% CI, − 1.129 to − 0.151; p = 0.010) with
high heterogeneity (I2 = 87.60%) (Fig. 2).
Risk of bias across studies
Small-study effects by means of visual inspection of fun-
nel plots was evaluated and the Egger’s regression asym-
metry test. As shown in Fig. 3, the funnel plot was
symmetrical and Egger’s linear regression tests provided
no evidence for existence of small-study effects (Egger
regression intercept, − 4.42 [95% CI, − 8.44 to 0.11, p =
0.052]).
Additional analysis
Regarding subgroup analysis, in obese individuals, phys-
ical exercise favored a reduction in fetuin-A the overall
same effect was not observed in individuals with obesity
(g = − 0.096; 95%CI, − 0.328 to 0.135; p = 0.415; I2 =
29.04%) and type 2 diabetes/dysglycemia (g = − 1.698;
95% CI, − 3.570 to 0.174; p = 0.075; I2 = 94.24%). The in-
dependent effects of potential moderating variables were
examined using meta-regression and are presented in
Fig. 4. The meta-regression analysis shows that there
was not a greater decrease in fetuin-A in individuals
who achieved greater BMI changes. The slope regression
coefficient was 0.065 [95% CI, − 0.185 to 0.315] and was
not significant (p = 0.609).
Finally, the influence analysis showed that no particu-
lar trial affected the pooled effect size (Fig. 5).
Discussion
To our knowledge, this is the first systematic review and
meta-analytic approach assessing the effects of super-
vised exercise training on fetuin-A in adults. The main
findings of our study are as follows: (i) supervised exer-
cise interventions is associated with reductions in
fetuin-A in adults and older participants; (ii) both aer-
obic and resistance exercise at vigorous or moderate
intensity, with a volume of 60 min/session and a mini-
mum frequency of 4 to 7 sessions/week, significantly re-
duced fetuin-A levels in dysglycemic and overweight/
obese individuals; and (iii) greater BMI reductions after
the supervised exercise intervention are not associated
with greater reductions in fetuin-A. These findings could
Ramírez-Vélez et al. Lipids in Health and Disease           (2019) 18:23 Page 4 of 11
help to provide more specific exercise recommendations
for cardiometabolic risk factor management in the adult
population. However, due to population heterogeneity
and the high risk of bias, our findings should be inter-
preted with caution.
Our results show that supervised exercise training alone
is associated with reductions in fetuin-A levels in adults.
This finding is consistent with recently published system-
atic reviews and meta-analyses showing that exercise sig-
nificantly modulates adipokine levels, inflammatory cy
tokine and glycemic control in youths [42] and patients
with type 2 diabetes [30]. Jenkins et al. [43] have suggested
an inverse correlation between cardiorespiratory fitness
and fetuin-A, which would suggest that physical fitness
level may regulate to some degree fetuin-A concentra-
tions. However, in contrast with this conclusion, Malin et
al., [27] showed that exercise-induced changes in fetuin-A
were not associated with cardiorespiratory fitness in
healthy adults. Two other narrative reviews [31, 44] also
suggested that exercise alone might improve adipokine
levels, such as fetuin-A. Our results show that supervised
exercise training on fetuin-A was statistically significant
when comparing post vs. pre-intervention values with
large heterogeneity (I2 = 87.60%), even though some of the
Fig. 1 Flow chart for the identification of the meta-analyses included in the study
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studies showed no changes after the exercise intervention.
However, these results should be treated with caution
given the limited number of studies included in our ana-
lysis. The differences between the results observed in the
analyses examining the effect of exercise could be due to
the large heterogeneity and lack of comparison with con-
trol groups. Also, these discrepancies can likely be ex-
plained by the wide range of characteristics of the
participants (> 50 years old, diseases, etc.), study duration,
intervention exercise program (i.e., cycling, treadmill and/
or elliptical, weight machines), and extent of change in
body composition across these studies.
Fetuin-A may attenuate lipogenesis and accelerate lip-
olysis in adipocytes, thereby promoting obesity and insulin
resistance [31]. Regarding both diseases and according to
subgroup analysis (individuals with type 2 diabetes/dysgly-
cemia or obese individuals), we found no evidence to
support that supervised exercise was associated with a
Table 1 Characteristics of the included trials
Study and design Sample Age
(years)
Type of
exercise
Exercise program
characteristics
Reduced
Fetuin-A
EPHPP
Lee et al. 2017 [30] Single-group
pre-post design
26 men (13 dysglycemic and
overweight) without CVD
51.1 Concurrent Total duration: 12 weeks
Frequency a week: 4
sessions
Duration per session: 60-min
Aerobic; Intensity: NR
Resistance; Intensity: NR
Yes 2
Malin et al. 2013 [28] Single-
group pre-post design
13 obese men and women with
nonalcoholic fatty liver disease
without CVD
50.5 Aerobic Total duration: 1 week
Frequency a week: 5
sessions
Duration per session: 60-min
Intensity: 85% HRmax
Yes 2
Malin et al. 2014[27] Single-
group pre-post design
20 older obese men and women
without CVD
66.3 Aerobic Total duration: 12 weeks
Frequency a week: 7
sessions
Duration per session: 60-min
Intensity: 85% HRmax
Yes 2
Mori et al. 2008[5] Single-group
pre-post design
8 men and women with type 2
diabetes mellitus
62.0 Aerobic Total duration: 12 weeks
Frequency a week: 3–5 sessions
Duration per session: 40-min
Intensity: 103 bpm
No 2
Schultes et al. 2010[39] Single-
group pre-post design
14 obese women and without
CVD
43.2 Aerobic Total duration: 6 weeks
Frequency a week: 3 sessions
Duration per session: 60-min
Intensity: 60% VO2peak
No 3
Wilund et al. 2010[40] RCT 17 hemodialysis men and women 59.9 Aerobic Total duration: 16 weeks
Frequency a week: 3
sessions
Duration per session: 45-min
Intensity: rate of perceived
exertion of 12–14
No 4
Winn et al. 2017 [21] Randomized trial
without a control group
18 obese men and women
without CVD
51.4 Aerobic Total duration: 4 weeks
Frequency a week: 4
sessions
Duration per session: NR
Intensity: 55% VO2peak or
80% VO2peak
No 5
Yang et al. 2011[29] Single-group
pre-post design
40 obese women without CVD 45.3 Concurrent Total duration: 12 weeks
Frequency a week: 5
sessions
Duration per session: 65-min
Aerobic; Intensity: 60–75% HRmax
Resistance; Intensity: NR
No 2
Zhang et al. 2017 [41] RCT 32 men and women with type 2
diabetes mellitus
47.2 Aerobic Total duration: 12 weeks
Frequency a week: 5 sessions
Duration per session: 70-min
Aerobic; Intensity: 70% HRmax
Yes 4
Bpm beats per minute, HRmax maximum heart rate.The methodological logical quality of non-randomized controlled trials and studies without control group (N =
8) was assessed using the Quality Assessment Tool for Quantitative Studies of the Effective Public Health Practice Project (EPHPP) (6 evaluation critical
methodological components). CVD, cardiovascular disease; RCT, randomised controlled trial
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reduction in serum fetuin-A levels. Stefan and associates
conducted a study involving a complex lifestyle interven-
tion program including dietary counseling and increased
physical activity and found different results. They reported
body weight decreased by ~ 3.2 kg, liver fat by 34%, and
energy and, in particular, saturated fat intake by 7 and
11%, respectively, and fetuin-A levels decreased over an ~
9-month period in subjects with a high risk for type 2 dia-
betes [45]. Recently, another randomized trial in obese
adults confirm our findings and did not detect significant
reductions in fetuin-A after applied two different exercise
programs at moderate and high intensity [21]. Therefore,
it is unclear whether these divergent findings are attribut-
able to differences in the duration and intensity of the
intervention, in health status, in the timing of fetuin-A
measurement (e.g., within 24 h versus 36–48 h after the
last exercise session), or in the sex of the participants;
however, there is some evidence that relationships be-
tween fetuin-A levels and “outcomes” vs. “status” exist
[45]. Reduced fetuin-A in response to intervention is often
associated with improvement in insulin-related parame-
ters [46], which was confirmed in all of the studies show-
ing decreases in this hepatokine. For example, the study
published by Lee et al. [30] demonstrated that changes in
circulating fetuin-A might predict some of the benefits
seen on insulin sensitivity after long-term exercise. An-
other study in older obese subjects also reveals that lower
fetuin-A after exercise correlated with lower hepatic insu-
lin resistance [27]. These authors suggest that fetuin-A
down regulates glucose transporter-4 translocation and
contributes to the improvement in skeletal muscle glucose
disposal after exercise.
The meta-regression analyses showed that there was
not a greater decrease in fetuin-A in individuals who
achieved greater BMI changes. These findings are partly
in accordance with those reported in adults with differ-
ent health statuses. For example, six weeks of supervised
aerobic exercise showed modest changes in body com-
position without affecting serum fetuin-A levels in obese
older women [39]; however, 12 weeks of aerobic-exercise
with significant weight loss did reduce plasma fetuin-A
levels in a study of obese older men and women [28].
Additionally, a recent review suggests that weight loss
seems to be effective for reducing fetuin-A level, which
is not consistent with our findings [31]. Some previous
studies suggest that dietary changes and weight loss [47]
as well as pharmacological treatment with thiazolidine-
diones [5] or metformin [48] might be more potent fac-
tors than aerobic exercise alone in the regulation of
hepatic fetuin-A release. Hennige et al. [49] also sug-
gested that fetuin-A induces low-grade inflammation
and represses adiponectin production in animals and in
humans. Collectively, it appears likely that hepatic fat con-
tent and thus serum fetuin-A levels respond to changes in
energy balance rather than to changes in body compos-
ition [39]. These data suggest an important role of fatty
liver in the pathophysiology of insulin resistance and
atherosclerosis. In this context, the decrease in fetuin-A
observed in the present study, along with changes in BMI,
could be interpreted as overall beneficial to reduce CVD
risk through supervised exercise training in humans.
Nonetheless, the disparate findings suggest more research
and comprehensive studies of changes in fetuin-A levels
as a function of exercise interventions and body compos-
ition change appears necessary.
The current meta-analytic approach was not designed to
establish the exact mechanism responsible for exercise re-
ducing fetuin-A in humans, but our data indicate that exer-
cise is associated with lower fetuin-A, as suggested
previously by others [45]. The plausible mechanisms by
which supervised exercise lowers fetuin-A include the fol-
lowing: (i) reducing intrahepatic fat content by down-re
gulating sterol regulatory element-binding protein-1c and
up-regulating peroxisome proliferator-activated receptor γ
Fig. 2 Forest plot for changes in fetuin-A. The black horizontal lines represent the 95% confidence intervals while the squares represent the
Hedge’s g estimate. The first red diamond represents the overall point estimate and 95% confidence intervals from all individual studies included
in each meta-analysis. All analyses are based on the random-effects model. RCT, randomized controlled trial
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expression levels [50]; (ii) decreasing hepatic glucolipotoxi-
city through modulating the reactive oxygen species, along
with inhibition of proinflammatory mediators [51]; and (iii)
activating protein kinase B (also known as Akt) and Akt
substrate of 160 kDa (AS160) phosphorylation, which itself
has been shown to improve glucose tolerance and decrease
insulin resistance [52].
The current study has several limitations. First, we in-
cluded both randomized controlled trials and clinical tri-
als, which introduced some risk of bias [53]. Second, there
is a high degree of heterogeneity among the analyzed
studies, in part due to the differences in inclusion criteria,
health status, and the type, intensity, and duration of the
supervised-exercise interventions within individual stud-
ies. Third, meta-analysis and meta-regression analyses in-
cluded a reduced number of studies, some of them with
small sample sizes and control groups (no intervention).
A high risk of bias (i.e., quality of the studies) could be
considered another limitation. Fourth, since this was an
aggregate data meta-analysis, the potential for ecological
fallacy exists. Fifth, since studies are not randomly
assigned to covariates in meta- analysis, they are consid-
ered to be observational in nature.
Consequently, the results of subgroup and meta-regres-
sion analyses conducted in our meta-analysis do not sup-
port causal inferences and should hence be viewed as
Fig. 3 Funnel plot of precision by difference in means (Hedge’s g). Circles represent the Hedge’s g for each study and the diamond represents
pooled Hedge’s g
Fig. 4 Meta-regression analysis of changes in body mass index (BMI) (X axis) against the Hedges’s g fetuin-A levels (Y axis)
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association. Large, well- designed randomized controlled
trials are needed to address this issue adequately. Given
the former, future randomized controlled trials may want
to address some of the differences and associations ob-
served in our current meta-analysis. In the same line, fu-
ture RCT studies would need to account for baseline
levels, change in other cardiometabolic traits in addition
to change in BMI, and effect of medication status, alcohol
and smoking patterns, and diet patterns throughout the
study period. Finally, since we ran a number of analyses,
some of our findings could have been nothing more than
chance occurrence. Therefore, the results should be taken
with caution, and more research on the effect of exercise
interventions is needed to reinforce the current recom-
mendation on exercise in the regulation of hepatic
fetuin-A in humans.
Conclusions
This meta-analysis shows that supervised exercise alone
is associated with reductions in fetuin-A levels in adults
and older participants. However, high quality random-
ized controlled trials describing the effects of supervised
exercise interventions on fetuin-A in adults are few.
Here in we have identify important components for fu-
ture research that should be addressed as well as the
limitations found in reviewing the studies for our ana-
lysis. By doing so, we hope to advance this area of re-
search and aid in the answering of questions on exercise,
hepatokines, and health, an area that is growing in inter-
est and importance.
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